Elanco Animal Health Incorporated
NYSEElanco Animal Health has moved decisively in the week since insiders were buying the dip — shorts are now covering, the stock is up 6%, and the insider thesis is playing out in real time. The short position is unwinding at a notable pace. Short interest dropped 13.6% in a single session on August 25, pulling the total down to 30.5 million shares, or 6.1% of the free float — down…
ELAN put/call ratio surges to 1.01, highest in 52 weeks, as options traders turn sharply defensive ahead of earnings—z-score of 4.27 signals extreme caution.
Elanco Animal Health has moved decisively in the week since insiders were buying the dip — shorts are now covering, the stock is up 6%, and the insider thesis is playing out in real time. The short position is…
Elanco Animal Health enters the back half of August with an unusually clear insider signal cutting against a bearish short position — the tension between those two forces defines the stock's setup heading into Q3. The…
Snapshot as of 20 Sept 2026
Elanco Animal Health heads into its August 7 earnings event with a striking reversal in options sentiment — one that stands in sharp contrast to the bullish tilt that defined positioning just days ago. The clearest…
Elanco Animal Health has now printed its Q2 results — the event the market spent last week pricing in — and the question shifts from anticipation to what the data reveals about positioning as the dust settles. The…
Elanco Animal Health heads into its August 5 earnings report with options traders leaning more bullish than usual and analysts steadily lifting targets — yet short sellers maintain a meaningful presence that keeps the…
Elanco Animal Health heads into the first week of June with a striking contradiction: short sellers have rebuilt positions aggressively while the company's own CEO put fresh money to work at the lows. Short interest…
Elanco Animal Health reports Q1 2026 results today against a backdrop of unusual insider conviction — the CEO buying shares at current prices just days before the earnings release. On May 15, CEO Jeff Simmons purchased…
Elanco Animal Health heads into its May 8 earnings with a striking divergence: the stock is up 20% on the week while the broader pharmaceutical peer group has crumbled. The price move alone commands attention. Elanco…
ELAN reported Q1 2026 results on May 6 that landed well ahead of consensus, and the stock's response has put short sellers firmly on the back foot. Adjusted EPS came in at $0.40 against a $0.35 estimate. Sales hit…
Elanco Animal Health reports Q1 2026 results on May 6 with the Street broadly constructive — but the stock has spent the past month drifting lower, testing how much of that optimism is already in the price. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ELAN — free to start on ORTEX.
Sign up for free →Open ELAN on ORTEX